New triple therapy aims to stop liver cancer from coming back

NCT ID NCT07618546

Not yet recruiting Disease control Sponsor: Henan Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether giving a combination of chemotherapy directly into the liver (HAIC) plus two drugs (camrelizumab and apatinib) before and after surgery can prevent liver cancer from returning in high-risk patients. About 208 people with resectable liver cancer and high-risk features will be randomly assigned to either the triple therapy plus surgery or surgery alone. The main goal is to see if the combo improves how long patients live without their cancer coming back.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: camrelizumab, apatinib mesylate, and FOLFOX-HAIC (oxaliplatin, leucovorin, 5-fluorouracil)
What this could lead to: If successful, this combination could lower the chance of liver cancer returning after surgery, improving long-term survival for high-risk patients.
What could go wrong: This is an early-stage trial with only 208 participants, so results may not apply to everyone. The drugs can cause serious side effects like immune reactions or liver damage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC - HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC - HEPATOCELLULAR CARCINOMA

More trials for these conditions

Other studies related to the condition(s) this trial covers.